Seraph® Clinical Trial
ExThera Medical has completed a multi-center, non-randomized European trial for the Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100). The study enrolled 15 patients at four centers in Germany.
The trial was designed to determine the safety and performance of the Seraph 100 for reducing bacteremia bioburden in patients on routine hemodialysis, with potential bacteria including MRSA, S. aureus, K. pneumoniae (CRE), K. pneumoniae, E. coli (CRE), E. coli, S. pneumoniae, E. faecalis, E. faecalis (VRE), E. faecium, A. baumannii, S. epidermidis, Methicillin resistant S. epidermidis, S. pyogenes, and Serratia marcescens.
For additional details about the study, visit: https://clinicaltrials.gov/show/NCT02914132